Mirum Pharmaceuticals Inc (MIRM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Mirum Pharmaceuticals Inc (MIRM) has a cash flow conversion efficiency ratio of -0.943x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-228.76 Million) by net assets ($242.49 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see MIRM market cap overview for the company's overall valuation and market capitalisation.
Mirum Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Mirum Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Mirum Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mirum Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Explore MIRM cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Elisa Oyj
HE:ELISA
|
0.117x |
|
Telecom Italia S.p.A
F:TQIR
|
0.082x |
|
Yunnan Wenshan Electric Power Co Ltd
SHG:600995
|
0.050x |
|
MarketAxess Holdings Inc
NASDAQ:MKTX
|
0.021x |
|
Associated Banc-Corp
NYSE:ASB
|
0.061x |
|
Sectra AB (publ)
ST:SECT-B
|
0.023x |
|
Blackstone Secured Lending Fund
NYSE:BXSL
|
0.094x |
|
Bezeq Israeli Telecommunication Corp Ltd
TA:BEZQ
|
0.313x |
Annual Cash Flow Conversion Efficiency for Mirum Pharmaceuticals Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Mirum Pharmaceuticals Inc from 2018 to 2025. View Mirum Pharmaceuticals Inc share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $314.69 Million | $55.83 Million | 0.177x | +287.69% |
| 2024-12-31 | $225.64 Million | $10.32 Million | 0.046x | +116.04% |
| 2023-12-31 | $248.67 Million | $-70.94 Million | -0.285x | +66.27% |
| 2022-12-31 | $142.04 Million | $-120.14 Million | -0.846x | +23.41% |
| 2021-12-31 | $120.21 Million | $-132.76 Million | -1.104x | -113.37% |
| 2020-12-31 | $172.09 Million | $-89.08 Million | -0.518x | -71.40% |
| 2019-12-31 | $130.35 Million | $-39.36 Million | -0.302x | -935.73% |
| 2018-12-31 | $-10.32 Million | $-373.00K | 0.036x | -- |
About Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille … Read more